SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.

09:12 31/03/2026

ShiSi Pharmaceutical Group (02005) has announced that its Ibrutinib has been approved by the China National Medical Products Administration for registration as an active pharmaceutical ingredient for use in marketed formulations, making it the third domestic company to receive approval.

SSY GROUP (02005) announced that the company's Upatinib has been approved by the China National Medical Products Administration to be registered as an active pharmaceutical ingredient for use in marketed formulations, making it the third domestic enterprise to receive approval. Upatinib is a JAK-1 inhibitor mainly used for the treatment of rheumatoid arthritis and Crohn's disease, as well as atopic dermatitis, psoriatic arthritis, ulcerative colitis, giant cell arteritis, etc.

HK Stock Market Move | BOC Hong Kong (02388) rose more than 5% after the performance announcement. Shareholders' attributable surplus increased by 4.9% year-on-year. The annual dividend increased by 6.8% compared to the previous year.

HK Stock Market Move | GT Gold (08299) rose by more than 31%, proposing to purchase all the shares of Changsheng United Investment for 585 million Hong Kong dollars to strengthen its mineral portfolio.

Chip stocks have fallen as a "cash machine" for risk aversion, with Micron (MU.US) and SK Hynix leading the semiconductor sector's worst single month in three and a half years.